BELGRADE, Mont. , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the Irix-C cervical cage for use with

BELGRADE, Mont. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical cases of the Xspan Laminoplasty Fixation System.

BELGRADE, Mont. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, reminds rights holders that the subscription period for its previously announced

BELGRADE, Mont. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has adjusted the subscription price and related pricing

*See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: Company revenue increased 10.5% to $23.1 million , as compared to pro forma revenue of $20.9 million in third quarter 2015 Gross profit increased to $16.0 million , as compared to pro forma third quarter

BELGRADE, Mont. , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE MKT LLC (the "Exchange") notified the Company that

BELGRADE, Mont. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has commenced the subscription period for its previously

BELGRADE, Mont. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, provides stockholders and convertible note holders a reminder of the Company’s

BELGRADE, Mont. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended September 30, 2016 , at the close of

*See footnote about the use of pro forma financial information Record Third Quarter 2016 Revenue in the range of $23.0 million to $23.3 million Third Quarter 2016 Revenue represents an increase of 10.0% to 11.5% compared to pro forma Third Quarter 2015 Revenue of $20.9 million and a sequential